A method of treating episodic and chronic nasal congestion of the human nasal passages is disclosed. The present invention combines use of decongestant nasal spray, saline nasal spray, and nasal dilator therapies with minimized risk of incurring rebound congestion. The method may be used as both preventative and withdrawal therapies for patients experiencing rebound congestion. Nasal dilators, decongestant nasal spray and saline nasal spray are provided in kit form whereby users may practice the method.

A liquid nebulizer (1) for medical uses wherein a dome-shaped body (10) is shaped symmetrically with respect to a first frontal median plane (M) and to a second sagittal median plane (N) intersected in a central axis (A); the dome-shaped body (10) being developed along the axis (A) between a base portion (100) and an upper truncated portion (102) provided with a cavity (1020); at least two channels (12)(12′) being provided, each of which shaped to access the cavity (1020) through a respective hole (120)(120′) arranged at a given distance from one of the first frontal median plane (M) and second sagittal median plane (N).

Systems, products, compounds and methods can be applied and/or used by a person to facilitate and promote the production of nitric oxide to be used by a person for health benefits. The systems, products, and devices include a nitric oxide nasal delivery system. The system can comprise one or more containers for compounds that when mixed are adapted to produce nitric oxide gas, at least one container with a nitrite compound and at least one container with an acid compound. Containers can be ruptured so that the compounds may be mixed and produce nitric oxide gas. The nitric oxide gas may then be delivered to a user via one or more of the nasal cavities and/or mouth.

Nonpathogenic microorganism preparations for delivery to the intranasal system, kits including nonpathogenic microorganism preparations for delivery to the intranasal system, and devices for administering nonpathogenic microorganism preparations to the intranasal system are provided. Vehicles for intranasal delivery of nonpathogenic microorganisms are provided. Ammonia oxidizing microorganism preparations for delivery to the intranasal system, kits including ammonia oxidizing preparations for delivery to the intranasal system, and devices for administering ammonia oxidizing preparations to the intranasal system are provided. Vehicles for intranasal delivery of ammonia oxidizing microorganisms are provided.

Disclosed is a family of intranasal spray dispensers for administering uniform low doses of desmopressin so as to achieve safe antidiuresis in human patients. The dispensers of the invention may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome where desmopressin therapy is useful or where safe temporary suppression of urine production may lead to beneficial health effects or increased convenience in voiding control.

Provided is an applicator for the dispensing of a powder such as a pharmaceutical powder, on a target location. Also, provided are methods of applying a powder on a surface using the applicator.

A spray device includes a mouthpiece that accommodates a spray nozzle unit. The spray nozzle unit is operatively connected to a liquid reservoir to receive a pressurized liquid to be sprayed. A connection between the spray nozzle unit and the liquid reservoir is effected by a flexible tube that connects at one end substantially fixedly to the mouth piece in fluid communication with the spray nozzle device. The liquid reservoir is interchangeably coupled to the opposite end of the flexible tube and, preferably, comprises a standard syringe. A spray delivery device comprises a holder for holding the syringe and has at least one manipulator member that is configured to impose an enhanced force on the plunger.

A dispenser for applying liquid, having a housing with an applicator opening and a liquid reservoir. The dispenser has a ventilation duct by which an ambient atmosphere is connected to the liquid reservoir so that, after the application of liquid, an inflow of air from the atmosphere is permitted into the liquid reservoir. The dispenser is provided with a detection installation which for detecting an application procedure detects air flowing in through the ventilation duct. The dispenser has a protective cap covering the applicator opening on the housing. The dispenser in the ventilation duct has a switch valve operable by activating a push-button on the external side of the housing. The protective cap acts on the push-button when placed on the housing or when the protective cap is being placed thereon to open the switch valve.

A nebulizer unit includes a housing, which includes an aerosol generator with a feed chamber disposed at one side, an ampoule receiver, an opening device with at least one opening, which is in communication with the feed chamber, and an ampoule with liquid, which comprises at least one opening, with which it can be inserted or used in the ampoule receiver, wherein the ampoule has a connection region, which interacts with a connector of the ampoule receptacle in order to hold the ampoule firmly in the ampoule receiver and to connect the openings and such that they are leak tight.

Systems and methods are provided for delivering one or more drugs. In some embodiments, a drug delivery system includes a housing having a distal end with an inlet through which an inspiratory flow of air passes into the housing, a proximal end having a patient interface attached thereto, the patient interface being configured to interface with a user, and an inspiratory flow pathway extending from the distal end to the proximal end of the housing. A nitric oxide (NO) source is positioned within the housing and is configured to deliver NO-containing gas to the patient interface. A secondary drug source is positioned within the housing and is configured to deliver a secondary drug to the patient interface. A controller is configured to control an amount of NO-containing gas and an amount of the secondary drug delivered using a control scheme.